Alphamab Oncology has announced research updates regarding its investigational drug JSKN003 at the ESMO Congress 2025, held from October 17 to October 21, 2025. The updates include data from a phase I/II clinical study evaluating the efficacy and safety of JSKN003 in Chinese patients with advanced solid tumors, specifically those with primary platinum-refractory ovarian cancer $(OC)$. As of June 13, 2025, a total of 26 patients received JSKN003 at a dose of 6.3mg/kg every three weeks. The company also outlined the ongoing phase III clinical trial, which aims to enroll 556 patients across 80 sites in China. Patient recruitment began in February 2025 and is ongoing. JSKN003 is described as a biparatopic HER2-targeting antibody-drug conjugate linked to a topoisomerase I inhibitor. The company cautioned that there is no guarantee of successful development or commercialization of JSKN003.